Basiliximab

Identification

Name
Basiliximab
Accession Number
DB00074 / 9927MT646M
Groups
Simulect
Description

A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that capabilities as an immunosuppressive agent, especially binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, additionally referred to as CD25 antigen) at the floor of activated T-lymphocytes. it's miles a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma mobile line genetically engineered to explicit plasmids containing the human heavy and light chain consistent location genes and mouse heavy and mild chain variable area genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.

Pharmacology

Pharmacodynamics

Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

Indication

For prophylactic treatment of kidney transplant rejection

Action

Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.